Purpose: We determined the value of mandatory second opinion pathology review to interpret prostate needle biopsy before radical prostatectomy. Materials and Methods: In all cases referred to our institution for radical prostatectomy in 1 year we compared pathological parameters in original and reviewed pathology reports, including benign, atypical or malignant diagnosis, final Gleason score, positive core number, core highest cancer percent and perineural invasion or extraprostatic extension. A major Gleason score discrepancy was defined as a change to a different risk category (6,7 and 8-10). We defined a significant difference in the highest percent of cancer in a core as 30% or greater. Results: Of the 855 cases originally diagnosed as prostatic adenocarcinoma cancer was confirmed in 844 (98.8%) by needle biopsy and prostatectomy, of which 9 (1%) were atypical and 2 (0.2%) were benign upon review. A major discrepancy in Gleason score was present in 124 cases (14.7%), of which 57 (46.0%) were upgraded and 67 (54%) were downgraded. Of cases with a final Gleason score of 6, 8.4% were originally diagnosed as 7 (7.8%) or 8-10 (0.6%), 21% with a final score of 7 had an original score of 6 (13.2%) or 8-10 (7.8%) and 21 of 61 (34%) with a score of 8-10 were originally diagnosed as 7 or less. There were 80 cases (64.5%) of disagreement between scores 6 and 7. Of the 777 cases with the positive core number in each
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Editorial Comment
This article by Brimo et al. emphasizes the importance of a second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy. It may result in significant differences that may affect therapy. Of the 855 cases originally diagnosed as prostatic adenocarcinoma, cancer was confirmed in 844 (98.8%) by needle biopsy and prostatectomy. Therefore, the rate of unconfirmed cancer was 1.2%. Of these unconfirmed cases 1% were "suspicious but not diagnostic" and 0.2% were benign.
The most common benign lesion that simulates adenocarcinoma is partial atrophy. The lesion was reported in the periodic literature in 1998 (1). Architecturally, partial atrophy consists of crowded glands often with a disorganized growth pattern. In contrast to complete atrophy, which can typically be diagnosed at scanning magnification owing to the presence of well-formed glands with a very basophilic appearance, partial atrophy has pale cytoplasm lateral to the nuclei giving rise to pale staining glands that more closely mimic cancer. An additional difficulty in distinguishing cancer from partial atrophy is the positivity for alpha-methylacyl coenzyme A racemase (AMACR) in some acini (2) (3) (4) .
